

22 September, 2013 – Lull Hall: 13:30 – 17:00 hours

Gran Via exhibition centre, Fira Barcelona, Spain



Joint symposium on the occasion of the 49th EASD Annual meeting

Opening a new chapter in diabetes research: recent results from the IMI diabetes consortia SUMMIT, IMIDIA & DIRECT



Programme

- 13:30 **Introduction & welcome** (M Mark, SUMMIT - W Kramer, IMIDIA – H Rütten, DIRECT)
- 13:35 **Welcome by EASD** (A Boulton, President EASD)
- 13:45 **IMI Address** (M Goldman, Executive Director Innovative Medicines Initiative)
- 13:55 **Collaborative discovery in diabetes research: the IMI DIABETES PLATFORM** (M Mark)

14:05 **SUMMIT – approaching diabetic complications** (Chair: L Groop, M Mark)

Objectives & opportunities (M Mark)

Diabetic nephropathy in type 1 & 2 diabetes – biological insights and translational opportunities from genetic & non-genetic biomarker analysis / Animal models: better replicating diabetes complications (M McCarthy, M Gomez)

Cardiovascular disease in type 2 diabetes – novel findings in genetics & ...omics / Making vascular complications visible (H Colhoun, J Nilsson)

Next steps & goals (L Groop)

15:15 Coffee break

15:30 **imidia – pancreatic β -cell: the key to diabetes** (Chair: W Kramer)

Objectives & opportunities (B Thorens)

Generation & characterization of human pancreatic β -cell lines suited for drug discovery research (R Scharfmann)

Creation of a unique biorepository of human pancreatic β -cell samples (A Schulte)

Bioinformatical identification of novel biomarker modules corresponding to diabetic phenotypes (M Ibberson)

Visualization of insulin turnover in the pancreatic β -cell (M Solimena)

Next steps & goals (A Ktorza)

16:30 **DIRECT – personalized medicines in type 2 diabetes** (Chair: H Rütten, E Pearson)

Objectives & opportunities (H Rütten)

First results from retrospective sample analysis (E Pearson)

Next steps & goals (E Pearson)

Change of treatment paradigms

3 collaborative European Public Private Partnerships will present their latest research on the pancreatic β -cell, personalized medicine in type 2 diabetes and late stage diabetic complications.

Under the umbrella of the Innovative Medicines Initiative (IMI, www.imi.europa.eu) these research partnerships bring together leading experts from numerous academic institutions, pharmaceutical companies and biotechs to jointly overcome key bottlenecks in today's drug development process on the way to

- better monitor, treat and prevent severe micro- and macrovascular diabetic complications

- slow down disease progression and ultimately find a cure for diabetes

- better understand diabetes heterogeneity for determining best treatment options for each patient.

Together they constitute **the IMI Diabetes Platform**, one of the most holistic discovery approaches in diabetes research to date.

Expected participation

The symposium is set-up to attract a wide audience. Diabetes researchers, clinicians, patient organizations, health care providers, politicians and decision makers are all encouraged to attend.

Contact:

Markus.Albertini@boehringer-
ingelheim.com / Peter.Hecht@aon.at /
Bernd.Jablonka@sanofi.com

17:00 End of meeting

The IMI diabetes projects receive support from the Innovative Medicines Initiative, resources which are composed of financial contribution from the European Union's FP7 and EFPIA companies' in kind contribution.

